中国肝癌多学科综合治疗专家共识

2020-12-20 中国抗癌协会肝癌专业委员会 中国医学前沿杂志(电子版).2020,12(12):28-36.

中国抗癌协会肝癌专业委员会组织全国肝癌领域不同专业的知名专家共同撰写了《中国肝癌多学科综合治疗专家共识》(以下简称本共识),本共识在《原发性肝癌诊疗规范(2019年版)》的基本框架下,旨在整合其他共识

中文标题:

中国肝癌多学科综合治疗专家共识

发布日期:

2020-12-20

简要介绍:

中国抗癌协会肝癌专业委员会组织全国肝癌领域不同专业的知名专家共同撰写了《中国肝癌多学科综合治疗专家共识》(以下简称本共识),本共识在《原发性肝癌诊疗规范(2019年版)》的基本框架下,旨在整合其他共识、指南在肝癌联合治疗策略中的最新进展,重点在于如何建立多学科诊疗团队(MDT)和对不同分期肝癌如何开展多学科综合治疗操作进行细化、更新和补充,为临床一线提供一部更全面、实操性强、符合中国国情的肝癌多学科综合治疗共识。期望本共识的推广应用能够对规范我国肝癌诊疗的临床行为、保障医疗质量和医疗安全、优化医疗资源发挥积极的推动作用。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国肝癌多学科综合治疗专家共识_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3f67a1c002032248, title=中国肝癌多学科综合治疗专家共识, enTitle=, guiderFrom=中国医学前沿杂志(电子版).2020,12(12):28-36., authorId=0, author=, summary=中国抗癌协会肝癌专业委员会组织全国肝癌领域不同专业的知名专家共同撰写了《中国肝癌多学科综合治疗专家共识》(以下简称本共识),本共识在《原发性肝癌诊疗规范(2019年版)》的基本框架下,旨在整合其他共识, cover=https://img.medsci.cn/20201230/1609258636462_2020535.jpg, journalId=0, articlesId=null, associationId=137, associationName=中国抗癌协会肝癌专业委员会, associationIntro=为中国抗癌协会的直属二级机构,中国抗癌协会肝癌专业委员会是我国肝癌学术领域最权威的机构,汇聚了全国各地肝癌研究领域的领先专家。致力于国内肝癌知识和技术的普及和推广。, copyright=0, guiderPublishedTime=Sun Dec 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>中国抗癌协会肝癌专业委员会组织全国肝癌领域不同专业的知名专家共同撰写了《中国肝癌多学科综合治疗专家共识》(以下简称本共识),本共识在《原发性肝癌诊疗规范(2019年版)》的基本框架下,旨在整合其他共识、指南在肝癌联合治疗策略中的最新进展,重点在于如何建立多学科诊疗团队(MDT)和对不同分期肝癌如何开展多学科综合治疗操作进行细化、更新和补充,为临床一线提供一部更全面、实操性强、符合中国国情的肝癌多学科综合治疗共识。期望本共识的推广应用能够对规范我国肝癌诊疗的临床行为、保障医疗质量和医疗安全、优化医疗资源发挥积极的推动作用。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=429, tagName=肝癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=429, guiderKeyword=肝癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10411, appHits=390, showAppHits=0, pcHits=796, showPcHits=10021, likes=2, shares=30, comments=13, approvalStatus=1, publishedTime=Wed Dec 30 00:24:21 CST 2020, publishedTimeString=2020-12-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Dec 30 00:17:21 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 23:20:54 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国肝癌多学科综合治疗专家共识_.pdf)])
中国肝癌多学科综合治疗专家共识_.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1210053, encodeId=aeef121005384, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e8108087, createdName=ms2000000804449592, createdTime=Sun Apr 10 16:15:21 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054084, encodeId=5b1110540846f, content=很喜欢,这个有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b22898247, createdName=daiht3, createdTime=Thu Sep 23 10:23:46 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014390, encodeId=8f8310143901d, content=喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:35 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014389, encodeId=882210143892c, content=很好,正需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955550, encodeId=691495555018, content=非常好,实用!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ca5478750, createdName=肥冬, createdTime=Fri Apr 09 18:51:37 CST 2021, time=2021-04-09, status=1, ipAttribution=)]
    2022-04-10 ms2000000804449592

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1210053, encodeId=aeef121005384, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e8108087, createdName=ms2000000804449592, createdTime=Sun Apr 10 16:15:21 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054084, encodeId=5b1110540846f, content=很喜欢,这个有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b22898247, createdName=daiht3, createdTime=Thu Sep 23 10:23:46 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014390, encodeId=8f8310143901d, content=喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:35 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014389, encodeId=882210143892c, content=很好,正需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955550, encodeId=691495555018, content=非常好,实用!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ca5478750, createdName=肥冬, createdTime=Fri Apr 09 18:51:37 CST 2021, time=2021-04-09, status=1, ipAttribution=)]
    2021-09-23 daiht3

    很喜欢,这个有用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1210053, encodeId=aeef121005384, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e8108087, createdName=ms2000000804449592, createdTime=Sun Apr 10 16:15:21 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054084, encodeId=5b1110540846f, content=很喜欢,这个有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b22898247, createdName=daiht3, createdTime=Thu Sep 23 10:23:46 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014390, encodeId=8f8310143901d, content=喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:35 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014389, encodeId=882210143892c, content=很好,正需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955550, encodeId=691495555018, content=非常好,实用!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ca5478750, createdName=肥冬, createdTime=Fri Apr 09 18:51:37 CST 2021, time=2021-04-09, status=1, ipAttribution=)]
    2021-09-03 148b8ccdm55暂无昵称

    喜欢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1210053, encodeId=aeef121005384, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e8108087, createdName=ms2000000804449592, createdTime=Sun Apr 10 16:15:21 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054084, encodeId=5b1110540846f, content=很喜欢,这个有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b22898247, createdName=daiht3, createdTime=Thu Sep 23 10:23:46 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014390, encodeId=8f8310143901d, content=喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:35 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014389, encodeId=882210143892c, content=很好,正需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955550, encodeId=691495555018, content=非常好,实用!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ca5478750, createdName=肥冬, createdTime=Fri Apr 09 18:51:37 CST 2021, time=2021-04-09, status=1, ipAttribution=)]
    2021-09-03 148b8ccdm55暂无昵称

    很好,正需要

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1210053, encodeId=aeef121005384, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e8108087, createdName=ms2000000804449592, createdTime=Sun Apr 10 16:15:21 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054084, encodeId=5b1110540846f, content=很喜欢,这个有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b22898247, createdName=daiht3, createdTime=Thu Sep 23 10:23:46 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014390, encodeId=8f8310143901d, content=喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:35 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014389, encodeId=882210143892c, content=很好,正需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12295325161, createdName=148b8ccdm55暂无昵称, createdTime=Fri Sep 03 21:40:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955550, encodeId=691495555018, content=非常好,实用!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ca5478750, createdName=肥冬, createdTime=Fri Apr 09 18:51:37 CST 2021, time=2021-04-09, status=1, ipAttribution=)]
    2021-04-09 肥冬

    非常好,实用!

    0

拓展阅读

2010 NACB医学实践指南:肝癌、膀胱癌、子宫颈癌、胃癌肿瘤标志物的应用

美国临床生化科学院(NACB,The National Academy of Clinical Biochemistry) · 2010-01-01

2011 CSLC/CSCO/CMA肝癌射频消融治疗规范的专家共识

中国抗癌协会肝癌专业委员会(CSLC,Chinese Society of Liver Cancer) · 2011-01-01

2011原发性肝癌局部消融治疗的专家共识

中国抗癌协会肝癌专业委员会(CSLC,Chinese Society of Liver Cancer) · 2011-01-01

2011 原发性肝癌规范化病理诊断方案专家共识

中国抗癌协会肝癌专业委员会(CSLC,Chinese Society of Liver Cancer) · 2011-04-01

原发性肝癌诊疗规范(2011年版)

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-10-14

中国肝癌肝移植临床实践指南(2014版)

中华医学会器官移植学分会 · 2014-07-15